Japan approves first self-amplifying mRNA COVID-19 vaccine from CSL, Arcturus
In a global first, Japans Ministry of Health, Labor and Welfare has approved CSL Ltd.’s and Arcturus Therapeutics Inc.’s self-amplifying messenger RNA (sa-mRNA) vaccine (ARCT-154) for COVID-19 in adults. The approval marks the first milestone for a November 2022 licensing deal under which CSL subsidiary CSL Seqirus in-licensed Arcturus’ late-stage sa-mRNA vaccine platform technology.
Arcturus Therapeutics Inc Japan Ministry Of Health Arcturus Therapeutics Csl Seqiris Arcturus Therapeutics Inc Meiji Seika Pharma Co Ltd
Source: bioworld.com